Search

everythinglearnresearchcommunity

for

Search:↓

A user underwent a hair transplant with 3200 grafts and plans to update others on their progress. They previously used minoxidil and finasteride to stabilize hair loss but opted for a transplant for better results.

Results for PP405 are expected next year, with concerns about its pricing and potential black market availability. Some users believe it may be slightly more effective than finasteride and dutasteride, and combining it with treatments like minoxidil and microneedling could be beneficial.

The conversation is about choosing an anti-androgen for hair loss treatment, with options being alfatradiol and pyrilutamide. Alfatradiol is considered a better choice due to its established use, while pyrilutamide is more experimental.

The conversation is about finding a reliable Chinese source for pyrilutamide or RU58841, ideally with a third-party Certificate of Analysis from Janoshik Analytical. The user is seeking recommendations for these hair loss treatments.

Pyrilutamide, a new drug being tested to combat hair loss that has been found to perform comparably or better than finasteride and dutasteride in the initial 6 months of treatment with minimal reported side effects.

KX-826 is undergoing trials for hair loss treatment, showing similar effectiveness between 0.5% and 1.0% dosages, with mild side effects compared to finasteride. Users discuss combining KX-826 with other treatments like minoxidil and clascoterone for better results.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A user shared their positive experience with a 3200 graft hair transplant surgery, costing 1.20 lakh INR, performed by a doctor with a background at Eugenix. Post-surgery, they were instructed to use minoxidil 5% topically, take finasteride tablets, and undergo PRP treatments.

Exosomes combined with fractional picosecond laser treatment were effective in treating androgenetic alopecia and promoting repigmentation in white hair patches. The role of exosomes in hair repigmentation, particularly in conditions like poliosis, is not well-studied.

People are discussing their reactions if PP405 fails in phase 3 trials, with some expressing skepticism and others holding onto hope for future treatments like GT20029 and Breezula. Many mention continuing with existing treatments like minoxidil and finasteride, while others express disappointment and consider alternative solutions.

The user is experiencing shedding of thick, healthy hair after using KX826 0.5% for a month. They are concerned about losing coverage and are seeking others' experiences with regrowth.

Hair loss treatment includes Minoxidil, Derma Rolling, PRP, Saw Palmetto, Vitamin D, and Pyri. After one month, Pyri caused penis numbness, tiredness, and reduced hair fall, but user stopped due to side effects.

A user had a 2250 graft hair transplant using both FUT and FUE methods, and is currently using finasteride, minoxidil, multivitamins, and biotin. Opinions vary on the effectiveness and appearance of the procedure, with some suggesting additional treatments or considering alternative options like shaving or using a hair system.

A user underwent a 5000 graft hair transplant in Istanbul, which included 900 beard grafts, after previously using finasteride with limited success. The procedure cost £4500, including transport and aftercare in both Istanbul and the UK.

The potential hair regrowth benefits of ASC-J9, a synthetic modified version of curcumin that is said to be more effective than Minoxidil and Finasteride. Reports from users suggest good thickening and temple regrowth with topical use at 0.025% concentration.

PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.

Hair loss treatments discussed include leave-in conditioner, volumizing powder, styling products, and hairspray for thicker appearance without fibers. User shares routine and product suggestions for people with thin hair that lacks volume.

A user who had a hair transplant in Turkey and shared their experience, as well as tips for those considering the same procedure. Other users then discussed their experiences with similar clinics, and offered advice on how to find reputable surgeons and avoid scams.

The FDA policy change may speed up approval for hair loss drugs like PP405, VDPHL-01, and Breezula by potentially eliminating the need for a second confirmatory Phase 3 trial. Approval timelines could be as early as 2028 for some treatments if Phase 3 results are strong.

Hair loss discussion includes treatments like Minoxidil, Finasteride, and RU58841. A secret to applying Toppik Hair Building Fibers is shared, and a possible reason is to help people apply Toppik.

Laser caps are found to be more effective than 5% minoxidil for treating hair loss, and when combined with minoxidil, they are even more effective. Some users report positive results with laser treatments, while others see no change; the devices are FDA approved, but opinions on their efficacy vary.

User had a 5000-hair FUT procedure in South Korea in 2014 and is satisfied with results. Uses Minoxidil, dermarolling, and Toppik hair fibers for crown area, and considering Finasteride.

RU58841 worsened hair condition, causing thinning and unusual patterns. The user stopped using it two months ago but hasn't seen recovery, and there's speculation about androgen receptor upregulation.

User RG737 considers hair system as last resort for hair loss, as finasteride and alternative remedies didn't work. Jeff-92 shares positive experience with hair system, suggesting to try it and push through initial doubts.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

The conversation discusses using cyproterone acetate at 12.5 mg to manage hair loss, with concerns about its effects on testosterone and potential health issues. Other treatments mentioned include finasteride, dutasteride, minoxidil, and RU58841, with varying experiences and outcomes.

A potential baldness cure, possibly PP405, might be available before the release of GTA 6, which is delayed to 2026 or 2027. There is skepticism about the effectiveness and release timeline of PP405.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

A user shared their positive experience with a non-surgical hair replacement system, detailing the purchase and maintenance process, including using Walker Lace Front Support Tape and various adhesives. They found the system secure and undetectable, allowing them to engage in active pursuits without issues.

The user discusses their experience with hair loss despite taking estrogen and cyproterone, and estimates needing around 3000 grafts for a feminine hairline. They are considering getting the procedure done in Turkey due to high European costs.